ScripData presented in two oral sessions at the American Society of Clinical Oncology on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) and the BCMAxCD3-directed bispecific antibody linvoseltamab illustrate
ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech
ScripA high-profile expert panel that included renowned clinician-scientist and director of the Cancer Science Institute of Singapore, Prof Ashok Venkitaraman, discussed some of the pressing global public
Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti